David M Mott - Net Worth and Insider Trading

David M Mott Net Worth

The estimated net worth of David M Mott is at least $1.6 Billion dollars as of 2024-12-03. David M Mott is the Director, 10% Owner of Tesaro Inc and owns about 10,434,803 shares of Tesaro Inc (TSRO) stock worth over $782 Million. David M Mott is the 10% Owner of Rhythm Pharmaceuticals Inc and owns about 4,909,956 shares of Rhythm Pharmaceuticals Inc (RYTM) stock worth over $299 Million. David M Mott is also the 10% Owner of Mirum Pharmaceuticals Inc and owns about 4,186,243 shares of Mirum Pharmaceuticals Inc (MIRM) stock worth over $193 Million. Besides these, David M Mott also holds Ra Pharmaceuticals Inc (RARX) , Adaptimmune Therapeutics PLC (ADAP) , AVEO Pharmaceuticals Inc (AVEO) , Millennial Media Inc (MM) , Trevi Therapeutics Inc (TRVI) , Ardelyx Inc (ARDX) , Surface Oncology Inc (SURF) , Imara Inc (IMRA) , Mersana Therapeutics Inc (MRSN) , Epizyme Inc (EPZM) , Novavax Inc (NVAX) , Regulus Therapeutics Inc (RGLS) , Dermira Inc (DERM) , Interleukin Genetics Inc (ILIU) , Achaogen Inc (AKAOQ) , Clovis Oncology Inc (CLVSQ) , Genocea Biosciences Inc (GNCAQ) , TRACON Pharmaceuticals Inc (TCON) , ARCA biopharma Inc (ABIO) , Appian Corp (APPN) . Details can be seen in David M Mott's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that David M Mott has not made any transactions after 2024-11-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of David M Mott

To

David M Mott Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, David M Mott owns 52 companies in total, including Epizyme Inc (EPZM) , Adaptimmune Therapeutics PLC (ADAP) , and Novavax Inc (NVAX) among others .

Click here to see the complete history of David M Mott’s form 4 insider trades.

Insider Ownership Summary of David M Mott

Ticker Comapny Transaction Date Type of Owner
EPZM Epizyme Inc 2021-03-26 director
ADAP Adaptimmune Therapeutics PLC 2020-07-01 director
NVAX Novavax Inc 2021-09-23 director
LIMIT LIMIT 2020-04-07 director
LIMIT LIMIT 2024-11-13 director
LIMIT LIMIT 2022-02-23 director
LIMIT LIMIT 2020-02-06 10 percent owner
LIMIT LIMIT 2020-01-29 10 percent owner
LIMIT LIMIT 2019-05-07 10 percent owner
LIMIT LIMIT 2019-12-12 10 percent owner
LIMIT LIMIT 2019-11-06 10 percent owner
LIMIT LIMIT 2019-10-30 10 percent owner
LIMIT LIMIT 2019-09-12 10 percent owner
LIMIT LIMIT 2019-07-22 10 percent owner
LIMIT LIMIT 2019-06-24 10 percent owner
LIMIT LIMIT 2019-06-07 director & 10 percent owner
LIMIT LIMIT 2019-05-09 10 percent owner
LIMIT LIMIT 2019-04-08 10 percent owner
LIMIT LIMIT 2019-01-22 director & 10 percent owner
LIMIT LIMIT 2018-12-14 10 percent owner
LIMIT LIMIT 2018-12-07 10 percent owner
LIMIT LIMIT 2018-10-17 10 percent owner
LIMIT LIMIT 2018-10-17 10 percent owner
LIMIT LIMIT 2018-10-04 10 percent owner
LIMIT LIMIT 2018-05-01 10 percent owner
LIMIT LIMIT 2018-04-23 10 percent owner
LIMIT LIMIT 2018-03-27 10 percent owner
LIMIT LIMIT 2018-03-09 10 percent owner
LIMIT LIMIT 2018-02-26 10 percent owner
LIMIT LIMIT 2017-11-27 10 percent owner
LIMIT LIMIT 2015-09-30 10 percent owner
LIMIT LIMIT 2018-01-01 10 percent owner
LIMIT LIMIT 2017-11-20 10 percent owner
LIMIT LIMIT 2017-11-06 10 percent owner
LIMIT LIMIT 2017-10-10 10 percent owner
LIMIT LIMIT 2016-12-19 10 percent owner
LIMIT LIMIT 2016-09-21 10 percent owner
LIMIT LIMIT 2016-07-29 10 percent owner
LIMIT LIMIT 2015-10-14 10 percent owner
LIMIT LIMIT 2015-03-11 10 percent owner
LIMIT LIMIT 2015-01-22 10 percent owner
LIMIT LIMIT 2014-11-25 10 percent owner
LIMIT LIMIT 2014-10-08 10 percent owner
LIMIT LIMIT 2014-08-06 10 percent owner
LIMIT LIMIT 2014-04-02 10 percent owner
LIMIT LIMIT 2014-01-09 10 percent owner
LIMIT LIMIT 2011-11-21 10 percent owner
LIMIT LIMIT 2012-10-11 10 percent owner
LIMIT LIMIT 2012-10-29 10 percent owner
LIMIT LIMIT 2018-12-07 10 percent owner
LIMIT LIMIT 2020-03-11 director
LIMIT LIMIT 2018-01-19 10 percent owner

David M Mott Latest Holdings Summary

David M Mott currently owns a total of 23 stocks. Among these stocks, David M Mott owns 10,434,803 shares of Tesaro Inc (TSRO) as of March 6, 2018, with a value of $782 Million and a weighting of 48.98%. David M Mott owns 4,909,956 shares of Rhythm Pharmaceuticals Inc (RYTM) as of October 10, 2017, with a value of $299 Million and a weighting of 18.71%. David M Mott also owns 4,186,243 shares of Mirum Pharmaceuticals Inc (MIRM) as of July 22, 2019, with a value of $193 Million and a weighting of 12.11%. The other 20 stocks Ra Pharmaceuticals Inc (RARX) , Adaptimmune Therapeutics PLC (ADAP) , AVEO Pharmaceuticals Inc (AVEO) , Millennial Media Inc (MM) , Trevi Therapeutics Inc (TRVI) , Ardelyx Inc (ARDX) , Surface Oncology Inc (SURF) , Imara Inc (IMRA) , Mersana Therapeutics Inc (MRSN) , Epizyme Inc (EPZM) , Novavax Inc (NVAX) , Regulus Therapeutics Inc (RGLS) , Dermira Inc (DERM) , Interleukin Genetics Inc (ILIU) , Achaogen Inc (AKAOQ) , Clovis Oncology Inc (CLVSQ) , Genocea Biosciences Inc (GNCAQ) , TRACON Pharmaceuticals Inc (TCON) , ARCA biopharma Inc (ABIO) , Appian Corp (APPN) have a combined weighting of 20.19% among all his current holdings.

Latest Holdings of David M Mott

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
TSRO Tesaro Inc 2018-03-06 10,434,803 74.96 782,192,833
RYTM Rhythm Pharmaceuticals Inc 2017-10-10 4,909,956 60.84 298,721,723
MIRM Mirum Pharmaceuticals Inc 2019-07-22 4,186,243 46.21 193,446,289
RARX Ra Pharmaceuticals Inc 2016-10-31 3,490,073 47.99 167,488,603
ADAP Adaptimmune Therapeutics PLC 2020-01-24 102,478,668 0.72 74,112,573
AVEO AVEO Pharmaceuticals Inc 2019-04-08 2,524,387 15.00 37,865,805
MM Millennial Media Inc 2012-10-29 8,196,614 1.75 14,344,075
TRVI Trevi Therapeutics Inc 2019-05-09 4,438,562 2.86 12,694,287
ARDX Ardelyx Inc 2024-11-13 1,425,465 5.54 7,897,076
SURF Surface Oncology Inc 2018-04-23 3,312,877 1.07 3,544,778
IMRA Imara Inc 2022-02-23 229,224 6.32 1,448,696
MRSN Mersana Therapeutics Inc 2020-04-07 538,599 2.30 1,238,778
EPZM Epizyme Inc 2021-03-26 257,859 1.47 379,053
NVAX Novavax Inc 2021-09-23 40,000 8.77 350,800
RGLS Regulus Therapeutics Inc 2019-05-07 205,245 1.63 334,549
DERM Dermira Inc 2014-10-02 17,241 18.75 323,269
ILIU Interleukin Genetics Inc 2016-07-29 55,418,811 0.00 249,385
AKAOQ Achaogen Inc 2016-12-19 5,215,128 0.03 130,378
CLVSQ Clovis Oncology Inc 2011-11-21 3,419,671 0.02 51,295
GNCAQ Genocea Biosciences Inc 2019-06-24 7,225,676 0.00 723
TCON TRACON Pharmaceuticals Inc 2018-03-27 17,330 0.03 558
ABIO ARCA biopharma Inc 2018-02-26 0 25.50 0
APPN Appian Corp 2017-11-27 0 38.86 0

Holding Weightings of David M Mott


David M Mott Form 4 Trading Tracker

According to the SEC Form 4 filings, David M Mott has made a total of 0 transactions in Tesaro Inc (TSRO) over the past 5 years. The most-recent trade in Tesaro Inc is the acquisition of 145,532 shares on March 6, 2018, which cost David M Mott around $8 Million.

According to the SEC Form 4 filings, David M Mott has made a total of 0 transactions in Rhythm Pharmaceuticals Inc (RYTM) over the past 5 years. The most-recent trade in Rhythm Pharmaceuticals Inc is the acquisition of 550,000 shares on October 10, 2017, which cost David M Mott around $9 Million.

According to the SEC Form 4 filings, David M Mott has made a total of 0 transactions in Mirum Pharmaceuticals Inc (MIRM) over the past 5 years. The most-recent trade in Mirum Pharmaceuticals Inc is the acquisition of 450,000 shares on July 22, 2019, which cost David M Mott around $7 Million.

More details on David M Mott's insider transactions can be found in the Insider Trading History of David M Mott table.

Insider Trading History of David M Mott

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

David M Mott Trading Performance

GuruFocus tracks the stock performance after each of David M Mott's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by David M Mott is 6.8%. GuruFocus also compares David M Mott's trading performance to market benchmark return within the same time period. The performance of stocks bought by David M Mott within 3 months outperforms 30 times out of 56 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how David M Mott's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of David M Mott

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
20 out of 55 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 7.23 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 6.27 LIMIT LIMIT LIMIT LIMIT LIMIT

David M Mott Ownership Network

Ownership Network List of David M Mott

No Data

Ownership Network Relation of David M Mott

Insider Network Chart

David M Mott Owned Company Details

What does Epizyme Inc do?

Who are the key executives at Epizyme Inc?

David M Mott is the director of Epizyme Inc. Other key executives at Epizyme Inc include Chief Scientific Officer Jeffery Kutok , Chief Operating Officer Jerald Korn , and Corporate Controller Joseph Beaulieu .

Epizyme Inc (EPZM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Epizyme Inc (EPZM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Epizyme Inc (EPZM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Epizyme Inc (EPZM)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Epizyme Inc Insider Transactions

No Available Data

David M Mott Mailing Address

Above is the net worth, insider trading, and ownership report for David M Mott. You might contact David M Mott via mailing address: 1119 St. Paul Street, Baltimore Md 21202.

Discussions on David M Mott

No discussions yet.